International Journal of Biomedicine. 2023;13(2):224-228.
DOI: 10.21103/Article13(2)_OA3
Originally published June 5, 2023
Background: The purpose of this study was to evaluate the efficacy of Aksaritmin (Aks) in comparison with Propafenone (Pr) for the prevention of atrial fibrillation (AF) in patients with none or minimal signs of structural heart disease.
Methods and Results: The study included 60 patients aged 18-70 years (mean age of 58.1±7.7 years) with paroxysmal (frequency of more than 2 paroxysms/3 months episodes of AF) or persistent AF with no or minimal signs of structural heart disease. The patients were divided into two groups: Group 1 included 30 patients taking Aks, and Group 2 included 30 patients taking Pr. According to the study protocol, the starting dose of Aks was 75 mg/day, with a possible dose increasing to 112.5 mg/day. The starting dose of Pr was 45 0mg/day, with a possible dose increase to 600 mg/day.
In Group 1, preventive efficacy of Aks was observed in 29(96.7%), 26(86.7%), and 24(80%) patients by 1-, 3- and 6-month follow-up, respectively. Of these, 26(86.7%), 22(73.9%), and 16(53.3%) patients showed absolute preventive efficacy of the drug. In Group 2, preventive efficacy of Pr was observed in 28(93.3%), 26(86.7%), and 23(76,7%) patients at 1-, 3- and 6-month follow-up, respectively. Of these, 25(83.3%), 21(70%), and 14(46.7%) patients showed absolute AAE of the Pr.
The initial recurrence rate of AF was 4.5±1.4 and 4.2±1.3 in Groups 1 and 2, respectively (P=0.3933 between groups); but after 3 and 6 months of therapy, the recurrence rate decreased to 0.7±1.1 (P<0.0001) and 0.8±1.3 (P<0.0001), and 0.8±1.0 (P<0.0001) and 1.1±1.0 (P<0.0001), respectively, which was statistically significant in both groups.
Conclusion: The preventive efficacy of Aks (including in combination with BB) at a dose of 75-112.5mg/day in recurrent forms of AF is comparable to the "reference" drug Pr at a dose of 450-600mg/day.
1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. Erratum in: Circulation. 2020 Jan 14;141(2):e33.
2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063.
3. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746-51. doi: 10.1093/eurheartj/eht280.
4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119.
5. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017 Apr 28;120(9):1501-1517. doi: 10.1161/CIRCRESAHA.117.309732.
6. Boriani G, Martignani C, Biffi M, Capucci A, Branzi A. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs. 2002;62(3):415-23. doi: 10.2165/00003495-200262030-00001.
7. Sokolov SF, Bakalov SA, Mironova NA, Rogova MM, Malkina TA, Golitsyn SP. [Efficiency and safety of allapinin in short- and long-term treatment of patients with normal heart and ventricular premature beats]. Kardiologiia. 2014;54(1):20-6. doi: 10.18565/cardio.2014.1.20-26. [Article in Russian].
8. Potupchik T, Veselova O, Evert L, Il'kova E. [Modern aspects of the use of allapinin in cardiac arrhythmias]. Vrach. 2015;2:1–2. [Article in Russian].
9. Dzhahangirov FN, Kasimova KR. [Preclinical toxicological study of the amount of alkaloids from Aconitum Septentrionale (aksaritmin)]. Infektsiia, immunitet i farmakologiia. 2009;1:26–30. [Article in Russian].
10. Dzhahangirov FN, Kasimova KR. [The study of acute toxicity and antiarrhythmic activity of the sum of alkaloids from Aconitum Septentrionale (aksaritmin)]. Farmacevticheskij vestnik Uzbekistana. 2009;2:67–70. [Article in Russian].
11. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019 Sep 4;9(9):CD005049. doi: 10.1002/14651858.CD005049.pub5.
12. Kushakovsky MS, Grishkin YuN. Cardiac arrhythmias. Cardiac arrhythmias and performance disorders. Guide for doctors. Foliant (med). 2017:109-110.
13. Vakhitova IuV, Farafontova EI, Khisamutdinova RIu, Iunusov VM, Cypasheva IP, Iunusov MS. [To the mechanisms of antiarrhythmic action of Allapinine]. Bioorg Khim. 2013 Jan-Feb;39(1):105-16. Russian. doi: 10.1134/s1068162013010111
14. Li J, Hu D, Song X, Han T, Gao Y, Xing Y. The Role of Biologically Active Ingredients from Natural Drug Treatments for Arrhythmias in Different Mechanisms. Biomed Res Int. 2017;2017:4615727. doi: 10.1155/2017/4615727.
15. Beik A, Joukar S, Najafipour H. A review on plants and herbal components with antiarrhythmic activities and their interaction with current cardiac drugs. J Tradit Complement Med. 2020 Apr 6;10(3):275-287. doi: 10.1016/j.jtcme.2020.03.002.
16. Tse G, Yan BP, Chan YW, Tian XY, Huang Y. Reactive Oxygen Species, Endoplasmic Reticulum Stress and Mitochondrial Dysfunction: The Link with Cardiac Arrhythmogenesis. Front Physiol. 2016 Aug 3;7:313. doi: 10.3389/fphys.2016.00313.
Download Article
Received April 20, 2023.
Accepted May 31, 2023.
©2023 International Medical Research and Development Corporation.
